Shots:
- Vincentage Pharma has reported topline P-III trial results evaluating VCT220 (120 0r 160mg, QD, PO) vs PBO for 52wks. in 840 Chinese adults with obesity or overweight with ≥1 weight-related comorbidity
- The trial met its 1EP, showing mean body weight reduction of -12.2% and -12.4% in the 120 & 160mg groups, respectively, vs -1.3% for PBO at 52wks., plus showed a safety profile consistent with existing GLP-1 therapeutics
- Also, Vincentage is planning to submit an NDA to NMPA for VCT220 for weight management in China in the near term
Ref: Globenewswire | Image: Vincentage Pharma | Press Release
Related News: Sanofi Reports P-II (ElevAATe) Trial Data on Efdoralprin alfa for Alpha-1 Antitrypsin Deficiency (AATD)-Related Emphysema
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
